Cargando…

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

Detalles Bibliográficos
Autores principales:	Cheng, Cheng, Wang, LingShu, Gall, Jason G. D., Nason, Martha, Schwartz, Richard M., McElrath, M. Juliana, DeRosa, Steven C., Hural, John, Corey, Lawrence, Buchbinder, Susan P., Nabel, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369566/ http://dx.doi.org/10.1371/annotation/805c32e9-70cf-4937-af15-e26de6a11e99

Ejemplares similares

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5
por: Toivonen, Raine, et al.
Publicado: (2012)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Use of adenovirus type-5 vectored vaccines: a cautionary tale
por: Buchbinder, Susan P, et al.
Publicado: (2020)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses
por: Bruder, Joseph T., et al.
Publicado: (2012)

Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells
por: Cheng, Cheng, et al.
Publicado: (2007)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Correction: Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses
por: Bruder, Joseph T., et al.
Publicado: (2012)

Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine
por: Schmidt, Katja G., et al.
Publicado: (2023)

A multiclade DNA/Ad vaccines for AIDS: the present and next generation
por: Nabel, Gary J
Publicado: (2006)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
por: Fitzpatrick, Zachary, et al.
Publicado: (2018)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

Adding unaligned sequences into an existing alignment using MAFFT and LAST
por: Katoh, Kazutaka, et al.
Publicado: (2012)

Adding Pluggable and Personalized Natural Control Capabilities to Existing Applications
por: Lamberti, Fabrizio, et al.
Publicado: (2015)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
por: Zahn, Roland, et al.
Publicado: (2012)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Spatio-Temporal History of HIV-1 CRF35_AD in Afghanistan and Iran
por: Eybpoosh, Sana, et al.
Publicado: (2016)

AD OK for 2K AD
Publicado: (1999)

Development of an Ad5H3 Chimera Using the “Antigen Capsid-Incorporation” Strategy for an Alternative Vaccination Approach
por: Gu, Linlin, et al.
Publicado: (2016)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Effects of Adding Neutralized Red Mud on the Hydration Properties of Cement Paste
por: Kang, Sukpyo, et al.
Publicado: (2020)

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
por: Zafar, Sadia, et al.
Publicado: (2020)

ad
por: Sefcik, Justine
Publicado: (2020)

Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions
por: Yang, Wei-Xiong, et al.
Publicado: (2016)

Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
por: Flickinger Jr, John C, et al.
Publicado: (2020)

LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)
por: Sobieszczyk, Magdalena, et al.
Publicado: (2021)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Winning grants step by step: the complete workbook for planning, developing, and writing successful proposals
por: O'Neal-McElrath, Tori, et al.
Publicado: (2013)

Ad hoc wireless networking
por: Xiuzhen Cheng, Xiuzhen, et al.
Publicado: (2003)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool
por: Liu, Yawu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3dbc81f58bqcqp43mv2seumise